简体
  • 简体中文
  • 繁体中文
×

热门资讯> 正文

在最新周期中没有为Neffy发布新的商业处方集添加或承保决定后，ARS Pharmaceuticals继续减少基于现金的运营费用

2026-06-25 04:13

  • Access and payer coverage: Despite certain payer discussions ongoing until mid-June, based on recent feedback, no new commercial formulary additions or coverage decisions have been issued for neffy in the July 1, 2026 cycle. ARS Pharma intends to continue working with the remaining payers, and notes that neffy remains broadly accessible to commercially insured patients with the combination of direct coverage and a recently introduced retail cash option at a price consistent with other epinephrine products. Demand has continued to grow independent of additional coverage additions. State Medicaid coverage has expanded with Florida adding neffy to its unrestricted Medicaid formulary effective July 1, 2026.
  • 2026 cash-based operating expenses: The Company has reduced its planned full-year 2026 cash-based operating expenses, excluding cost of goods sold (COGS), to approximately $248 million, reflecting prioritized commercial investment and enhanced cost discipline in the second half of 2026.
  • 2027 outlook: Combined with continued growth in the neffy base business, the Company reaffirms that its base business provides a path to reach cash-flow breakeven in 2027.
  • Base business supports expansion to CSU: ARS Pharma intends to build a profitable, growing commercial franchise around neffy that will underpin the Company’s financial trajectory and fund its pipeline development. The Company’s Phase 2b trial evaluating its intranasal technology for acute flares in CSU has completed enrollment of its interim population and interim data are expected in the fourth quarter of 2026. ARS Pharma views CSU as a potential significant future growth driver, with an estimated 1.6 million patients affected in the U.S. alone.

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
问答大全
（工作日09：30 - 次日05：30）
客户端：
关注我们：
  • 微信公众号二维码

© 2026 深圳市时代华盛网络科技有限公司版权所有 粤ICP备16068286号